Tus%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520qd

*Please note: The drug name provided ("Tus%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520qd") appears to be encoded and may not represent a standard drug name. I will proceed with information for **Tussionex® Pennkinetic® Extended-Release Suspension** (hydrocodone polistirex and chlorpheniramine polistirex), a common combination cough product. If the intended drug is different, please resubmit with the correct name.* # Tussionex® Pennkinetic® Extended-Release Suspension ## Overview Tussionex Pennkinetic is an extended-release liquid combination product containing an opioid antitussive (hydrocodone) and an antihistamine (chlorpheniramine). The polistirex formulations are designed for prolonged release. ## Primary Indications Symptomatic relief of cough and respiratory symptoms associated with colds and similar conditions. ## Adult Dosing * **Dosage:** 5 mL to 10 mL every 12 hours. * **Maximum:** Not to exceed 20 mL in 24 hours. ## Pediatric Dosing * **Age 6 to <12 years:** 5 mL every 12 hours. * **Age <6 years:** Safety and efficacy have not been established. Use is not recommended. ## Dose Adjustments * **Hepatic or Renal Impairment:** No specific dose adjustments are established. Caution and close monitoring are advised due to the potential for accumulation of hydrocodone and its metabolites. ## Contraindications * Hypersensitivity to hydrocodone or chlorpheniramine. * Respiratory depression. * Acute or severe asthma, or other conditions where bronchospasm may be precipitated. * Known or suspected paralytic ileus. * Use in children younger than 6 years. ## Adverse Effects * **Common:** Drowsiness, dizziness, constipation, nausea, vomiting, dry mouth, blurred vision, confusion. * **Serious:** Respiratory depression, addiction, dependence, tolerance, abuse, potentiation of other CNS depressants, bradycardia, hypotension, seizures (especially in children). ## Key Drug Interactions * **CNS Depressants (e.g., alcohol, benzodiazepines, opioids, sedatives):** Additive sedative and respiratory depressant effects; potentially fatal. * **MAO Inhibitors:** Potentiated and/or unpredictable effects; avoid concurrent use and for 14 days after discontinuing MAOIs. * **Strong CYP3A4 Inhibitors (e.g., ritonavir, ketoconazole):** Increased hydrocodone plasma concentrations. ## Monitoring * Respiratory rate and depth. * Level of consciousness and sedation. * Bowel function (for constipation). * Signs of abuse or dependence. ## Clinical Pearls * The extended-release formulation is not intended for rapid symptom relief. * Tussionex contains hydrocodone, an opioid, and carries a risk of addiction, abuse, and misuse, which can lead to overdose and death. * Due to the risk of profound sedation and respiratory depression, concomitant use with CNS depressants should be avoided or closely monitored. * The risk of respiratory depression is greatest when initiating therapy or increasing the dose. *** **Disclaimer:** This information is intended for clinical pharmacists and prescribers. It is not exhaustive and does not replace professional clinical judgment. Always refer to the most current prescribing information and consult with the prescribing physician. Dosing may vary based on individual patient factors and local protocols.